Cargando…

Bayesian regularization to predict neuropsychiatric adverse events in smoking cessation with pharmacotherapy

BACKGROUND: Research on risk factors for neuropsychiatric adverse events (NAEs) in smoking cessation with pharmacotherapy is scarce. We aimed to identify predictors and develop a prediction model for risk of NAEs in smoking cessation with medications using Bayesian regularization. METHODS: Bayesian...

Descripción completa

Detalles Bibliográficos
Autores principales: Truong, Van Thi Thanh, Green, Charles, Pedroza, Claudia, Hwang, Lu-Yu, Rajan, Suja S., Suchting, Robert, Cinciripini, Paul, Tyndale, Rachel F., Lerman, Caryn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148544/
https://www.ncbi.nlm.nih.gov/pubmed/37118656
http://dx.doi.org/10.1186/s12874-023-01931-7
_version_ 1785034996229079040
author Truong, Van Thi Thanh
Green, Charles
Pedroza, Claudia
Hwang, Lu-Yu
Rajan, Suja S.
Suchting, Robert
Cinciripini, Paul
Tyndale, Rachel F.
Lerman, Caryn
author_facet Truong, Van Thi Thanh
Green, Charles
Pedroza, Claudia
Hwang, Lu-Yu
Rajan, Suja S.
Suchting, Robert
Cinciripini, Paul
Tyndale, Rachel F.
Lerman, Caryn
author_sort Truong, Van Thi Thanh
collection PubMed
description BACKGROUND: Research on risk factors for neuropsychiatric adverse events (NAEs) in smoking cessation with pharmacotherapy is scarce. We aimed to identify predictors and develop a prediction model for risk of NAEs in smoking cessation with medications using Bayesian regularization. METHODS: Bayesian regularization was implemented by applying two shrinkage priors, Horseshoe and Laplace, to generalized linear mixed models on data from 1203 patients treated with nicotine patch, varenicline or placebo. Two predictor models were considered to separate summary scores and item scores in the psychosocial instruments. The summary score model had 19 predictors or 26 dummy variables and the item score model 51 predictors or 58 dummy variables. A total of 18 models were investigated. RESULTS: An item score model with Horseshoe prior and 7 degrees of freedom was selected as the final model upon model comparison and assessment. At baseline, smokers reporting more abnormal dreams or nightmares had 16% greater odds of experiencing NAEs during treatment (regularized odds ratio (rOR) = 1.16, 95% credible interval (CrI) = 0.95 – 1.56, posterior probability P(rOR > 1) = 0.90) while those with more severe sleep problems had 9% greater odds (rOR = 1.09, 95% CrI = 0.95 – 1.37, P(rOR > 1) = 0.85). The prouder a person felt one week before baseline resulted in 13% smaller odds of having NAEs (rOR = 0.87, 95% CrI = 0.71 – 1.02, P(rOR < 1) = 0.94). Odds of NAEs were comparable across treatment groups. The final model did not perform well in the test set. CONCLUSIONS: Worse sleep-related symptoms reported at baseline resulted in 85%—90% probability of being more likely to experience NAEs during smoking cessation with pharmacotherapy. Treatment for sleep disturbance should be incorporated in smoking cessation program for smokers with sleep disturbance at baseline. Bayesian regularization with Horseshoe prior permits including more predictors in a regression model when there is a low number of events per variable. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12874-023-01931-7.
format Online
Article
Text
id pubmed-10148544
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101485442023-04-30 Bayesian regularization to predict neuropsychiatric adverse events in smoking cessation with pharmacotherapy Truong, Van Thi Thanh Green, Charles Pedroza, Claudia Hwang, Lu-Yu Rajan, Suja S. Suchting, Robert Cinciripini, Paul Tyndale, Rachel F. Lerman, Caryn BMC Med Res Methodol Research BACKGROUND: Research on risk factors for neuropsychiatric adverse events (NAEs) in smoking cessation with pharmacotherapy is scarce. We aimed to identify predictors and develop a prediction model for risk of NAEs in smoking cessation with medications using Bayesian regularization. METHODS: Bayesian regularization was implemented by applying two shrinkage priors, Horseshoe and Laplace, to generalized linear mixed models on data from 1203 patients treated with nicotine patch, varenicline or placebo. Two predictor models were considered to separate summary scores and item scores in the psychosocial instruments. The summary score model had 19 predictors or 26 dummy variables and the item score model 51 predictors or 58 dummy variables. A total of 18 models were investigated. RESULTS: An item score model with Horseshoe prior and 7 degrees of freedom was selected as the final model upon model comparison and assessment. At baseline, smokers reporting more abnormal dreams or nightmares had 16% greater odds of experiencing NAEs during treatment (regularized odds ratio (rOR) = 1.16, 95% credible interval (CrI) = 0.95 – 1.56, posterior probability P(rOR > 1) = 0.90) while those with more severe sleep problems had 9% greater odds (rOR = 1.09, 95% CrI = 0.95 – 1.37, P(rOR > 1) = 0.85). The prouder a person felt one week before baseline resulted in 13% smaller odds of having NAEs (rOR = 0.87, 95% CrI = 0.71 – 1.02, P(rOR < 1) = 0.94). Odds of NAEs were comparable across treatment groups. The final model did not perform well in the test set. CONCLUSIONS: Worse sleep-related symptoms reported at baseline resulted in 85%—90% probability of being more likely to experience NAEs during smoking cessation with pharmacotherapy. Treatment for sleep disturbance should be incorporated in smoking cessation program for smokers with sleep disturbance at baseline. Bayesian regularization with Horseshoe prior permits including more predictors in a regression model when there is a low number of events per variable. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12874-023-01931-7. BioMed Central 2023-04-29 /pmc/articles/PMC10148544/ /pubmed/37118656 http://dx.doi.org/10.1186/s12874-023-01931-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Truong, Van Thi Thanh
Green, Charles
Pedroza, Claudia
Hwang, Lu-Yu
Rajan, Suja S.
Suchting, Robert
Cinciripini, Paul
Tyndale, Rachel F.
Lerman, Caryn
Bayesian regularization to predict neuropsychiatric adverse events in smoking cessation with pharmacotherapy
title Bayesian regularization to predict neuropsychiatric adverse events in smoking cessation with pharmacotherapy
title_full Bayesian regularization to predict neuropsychiatric adverse events in smoking cessation with pharmacotherapy
title_fullStr Bayesian regularization to predict neuropsychiatric adverse events in smoking cessation with pharmacotherapy
title_full_unstemmed Bayesian regularization to predict neuropsychiatric adverse events in smoking cessation with pharmacotherapy
title_short Bayesian regularization to predict neuropsychiatric adverse events in smoking cessation with pharmacotherapy
title_sort bayesian regularization to predict neuropsychiatric adverse events in smoking cessation with pharmacotherapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148544/
https://www.ncbi.nlm.nih.gov/pubmed/37118656
http://dx.doi.org/10.1186/s12874-023-01931-7
work_keys_str_mv AT truongvanthithanh bayesianregularizationtopredictneuropsychiatricadverseeventsinsmokingcessationwithpharmacotherapy
AT greencharles bayesianregularizationtopredictneuropsychiatricadverseeventsinsmokingcessationwithpharmacotherapy
AT pedrozaclaudia bayesianregularizationtopredictneuropsychiatricadverseeventsinsmokingcessationwithpharmacotherapy
AT hwangluyu bayesianregularizationtopredictneuropsychiatricadverseeventsinsmokingcessationwithpharmacotherapy
AT rajansujas bayesianregularizationtopredictneuropsychiatricadverseeventsinsmokingcessationwithpharmacotherapy
AT suchtingrobert bayesianregularizationtopredictneuropsychiatricadverseeventsinsmokingcessationwithpharmacotherapy
AT cinciripinipaul bayesianregularizationtopredictneuropsychiatricadverseeventsinsmokingcessationwithpharmacotherapy
AT tyndalerachelf bayesianregularizationtopredictneuropsychiatricadverseeventsinsmokingcessationwithpharmacotherapy
AT lermancaryn bayesianregularizationtopredictneuropsychiatricadverseeventsinsmokingcessationwithpharmacotherapy